Stock PHARM PHARMING GROUP N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Pharming Group N.V.

Equities

PHARM

NL0010391025

Pharmaceuticals

Market Closed - Euronext Amsterdam
Other stock markets
 11:35:00 2024-04-26 am EDT 		5-day change 1st Jan Change
0.9 EUR +2.16% Intraday chart for Pharming Group N.V. +2.16% -12.71%
Apr. 22 Pharming Group to Buy Back EUR123 Million of Bonds due 2025 MT
Apr. 18 Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 989.6 811.6 502.8 707.2 690.2 606.1 - -
Enterprise Value (EV) 1 975.2 765.7 457.1 637.6 619.7 515.2 486.7 454.6
P/E ratio 29 x 26.5 x 37.1 x - -74.7 x -300 x 40.9 x 10.6 x
Yield - - - - - - - -
Capitalization / Revenue 5.85 x 4.37 x 2.78 x 3.62 x 3.08 x 2.31 x 2.02 x 1.76 x
EV / Revenue 5.77 x 4.12 x 2.53 x 3.27 x 2.76 x 1.97 x 1.62 x 1.32 x
EV / EBITDA 14.8 x 10.1 x 8.9 x 21.4 x 64.4 x 50.8 x 16 x 6.56 x
EV / FCF 24.1 x 12.4 x 21.5 x 24.4 x -35.9 x 20.8 x 14.6 x 7.9 x
FCF Yield 4.14% 8.09% 4.66% 4.1% -2.78% 4.8% 6.87% 12.7%
Price to Book 9.45 x 5.55 x - - 3.44 x - - -
Nbr of stocks (in thousands) 631,323 638,056 648,749 652,414 669,406 673,438 - -
Reference price 2 1.568 1.272 0.7750 1.084 1.031 0.9000 0.9000 0.9000
Announcement Date 3/5/20 3/4/21 3/17/22 3/16/23 3/14/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 169 185.7 180.7 195.1 224.1 262 300.5 344.7
EBITDA 1 66.08 75.74 51.35 29.82 9.629 10.15 30.44 69.28
EBIT 1 60.91 67.42 33.53 17.3 -4.922 -7.146 6.472 38.22
Operating Margin 36.03% 36.31% 18.55% 8.87% -2.2% -2.73% 2.15% 11.09%
Earnings before Tax (EBT) 1 46.68 39.27 20.97 14.22 -10.98 3.446 18.95 51.94
Net income 1 36.2 32.65 14.54 12.98 -9.246 1.335 14.11 41.26
Net margin 21.41% 17.58% 8.04% 6.65% -4.12% 0.51% 4.7% 11.97%
EPS 2 0.0540 0.0480 0.0209 - -0.0138 -0.003000 0.0220 0.0850
Free Cash Flow 1 40.38 61.96 21.29 26.17 -17.25 24.75 33.42 57.53
FCF margin 23.89% 33.37% 11.78% 13.41% -7.7% 9.44% 11.12% 16.69%
FCF Conversion (EBITDA) 61.11% 81.82% 41.45% 87.76% - 243.85% 109.81% 83.04%
FCF Conversion (Net income) 111.57% 189.76% 146.44% 201.67% - 1,854.09% 236.82% 139.43%
Dividend per Share - - - - - - - -
Announcement Date 3/5/20 3/4/21 3/17/22 3/16/23 3/14/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4
Net sales 1 88.59 78.74 45.62 62.43 44.22 49.02 94.59 53.87 51.84 38.75 50.2 89.1 63 74.19 64.27 66.1 - 66.1 66.23
EBITDA - - - - - - - - - - - - - - - - - - -
EBIT 1 - - 9.74 7.613 - 17.42 - 7.712 -9.658 -12.45 4.845 - 1.795 1.005 1.882 -1.992 - 54.93 -70.73
Operating Margin - - 21.35% 12.19% - 35.54% - 14.31% -18.63% -32.12% 9.65% - 2.85% 1.35% 2.93% -3.01% - 83.1% -106.79%
Earnings before Tax (EBT) 1 25.9 16.91 1.14 3.583 4.015 19.12 23.25 9.217 -17.16 -15.19 3.096 -12.15 3.117 -1.827 6.852 5.373 22.03 29.76 -35.66
Net income 1 18.14 12.12 -0.3616 3.213 3.283 15.35 18.77 9.04 -13.88 -11.12 1.206 -9.957 3.306 -2.467 6.026 4.547 18.73 28.89 -36.54
Net margin 20.48% 15.39% -0.79% 5.15% 7.42% 31.31% 19.85% 16.78% -26.78% -28.7% 2.4% -11.18% 5.25% -3.33% 9.38% 6.88% - 43.7% -55.16%
EPS 0.0250 0.0160 -0.000860 - - - - 0.0129 - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - - - - - - - -
Announcement Date 7/30/20 8/5/21 10/28/21 3/17/22 5/12/22 8/4/22 8/4/22 10/27/22 3/16/23 5/11/23 8/3/23 8/3/23 10/26/23 3/14/24 - - - - -
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 14.4 46 45.6 69.7 70.5 90.9 119 151
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 40.4 62 21.3 26.2 -17.3 24.7 33.4 57.5
ROE (net income / shareholders' equity) 43.5% 26% - - -4.98% - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 0.1700 0.2300 - - 0.3000 - - -
Cash Flow per Share 0.1100 0.1100 - - - - - -
Capex 1 2.36 12 12.8 1.86 1.32 4.99 5.23 5.54
Capex / Sales 1.4% 6.46% 7.06% 0.95% 0.59% 1.9% 1.74% 1.61%
Announcement Date 3/5/20 3/4/21 3/17/22 3/16/23 3/14/24 - - -
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Pharming Group N.V.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.9 EUR
Average target price
2 EUR
Spread / Average Target
+122.22%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
PHARMING GROUP N.V. Stock Pharming Group N.V.
-12.71% 647M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PHARM Stock
  4. Financials Pharming Group N.V.